Back to Search Start Over

Myeloproliferative Neoplasms and Cardiovascular Disease: A Review.

Authors :
Leiva O
Liu O
Zhou S
How J
Lee M
Hobbs G
Source :
Current treatment options in oncology [Curr Treat Options Oncol] 2024 Oct; Vol. 25 (10), pp. 1257-1267. Date of Electronic Publication: 2024 Sep 16.
Publication Year :
2024

Abstract

Opinion Statement: Myeloproliferative neoplasms (MPN) are a heterogenous group of disorders of clonal hematopoiesis characterized by constitutive activation of the JAK/STAT signaling pathway leading to proliferation of blood cells. Cardiovascular disease (CVD) contributes significantly to the morbidity and mortality of patients with MPN. Particularly well-known CVD complications of MPNs are arterial and venous thrombotic events. However, MPNs are also associated with other forms of CVD including atrial fibrillation, heart failure, and pulmonary hypertension. Recent studies have characterized outcomes of patients with MPN and CVD, including acute myocardial infarction (AMI), heart failure, atrial fibrillation, and pulmonary hypertension. Additionally, optimal cardiovascular disease prevention strategies in patients with MPN are not yet clear. Further investigation is warranted to improve CVD outcomes in patients with MPN. Clinicians should be aware of cardiovascular complications of MPN, including thrombotic as well as non-thrombotic complications (heart failure, arrhythmias, pulmonary hypertension).<br /> (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Details

Language :
English
ISSN :
1534-6277
Volume :
25
Issue :
10
Database :
MEDLINE
Journal :
Current treatment options in oncology
Publication Type :
Academic Journal
Accession number :
39278999
Full Text :
https://doi.org/10.1007/s11864-024-01255-8